Oh DY - Search Results

1

Intratumoral CD4⁺ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Oh DY, et al. Cell. 2020 Jun 25;181(7):1612-1625.e13. doi: 10.1016/j.cell.2020.05.017. Epub 2020 Jun 3. Cell. 2020. PMID: 32497499 Free PMC article.

2

On the Verge: Immunotherapy for Colorectal Carcinoma.

Oh DY, Venook AP, Fong L. Oh DY, et al. J Natl Compr Canc Netw. 2015 Aug;13(8):970-8. doi: 10.6004/jnccn.2015.0117. J Natl Compr Canc Netw. 2015. PMID: 26285242 Review.

3

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.

Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. Oh DY, et al. Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28. Cancer Res. 2017. PMID: 28031229 Free PMC article.

4

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.

Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Hagihara K, et al. Among authors: oh dy. Oncoimmunology. 2018 Oct 1;8(1):e1486953. doi: 10.1080/2162402X.2018.1486953. eCollection 2019. Oncoimmunology. 2018. PMID: 30546940 Free PMC article.

5

Immunity in the Time of Metastases.

Oh DY, Fong L. Oh DY, et al. Immunity. 2018 Dec 18;49(6):1002-1003. doi: 10.1016/j.immuni.2018.12.008. Immunity. 2018. PMID: 30566878 Free article.

6

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Pai CS, et al. Among authors: oh dy. Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006. Epub 2019 Feb 5. Immunity. 2019. PMID: 30737146 Free PMC article.

7

TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.

Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. Looney TJ, et al. Front Immunol. 2020 Jan 9;10:2985. doi: 10.3389/fimmu.2019.02985. eCollection 2019. Front Immunol. 2020. PMID: 31993050 Free PMC article.

8

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.

Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Cham J, et al. Among authors: oh dy. J Immunother Cancer. 2020 May;8(1):e000368. doi: 10.1136/jitc-2019-000368. J Immunother Cancer. 2020. PMID: 32376721 Free PMC article. Clinical Trial.

9

An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.

Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. Wei J, et al. Among authors: oh dy. Mol Imaging Biol. 2020 Dec;22(6):1553-1561. doi: 10.1007/s11307-020-01527-3. Epub 2020 Aug 19. Mol Imaging Biol. 2020. PMID: 32813112 Free PMC article.

10

Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L. Zhang L, et al. Among authors: oh dy. Cancer Immunol Res. 2020 Dec;8(12):1496-1507. doi: 10.1158/2326-6066.CIR-20-0252. Epub 2020 Sep 23. Cancer Immunol Res. 2020. PMID: 32967912 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

755 results

Search Page